Probelte Pharma SL was awarded a grant from the Murcia Regional Development Agency’s grant programme to encourage SMEs in the region to procure innovation and competitiveness services, co-funded by the European Regional Development Fund. File: 2024.08.hino.000112
The aim of this project was to promote a more efficient business environment, helping to deliver the benefits of tax credits to support business innovation
Probelte Pharma awarded the Plimsoll Certificate of Business Excellence 2023
Probelte Pharma SL, a manufacturer of allergen and bacterial immunotherapy products, has been awarded the Plimsoll Certificate of Business Excellence 2023. According to its latest "Pharmaceutical Manufacturers & Distributors (Spain)" report, the Murcia-based company is ranked 66th, with the highest profit margin out of the 576 companies analysed in the sector.
The Plimsoll report provides an expert sectoral analysis of the financial and market situation of companies in Spain. Through this certification, we have cemented our position as one of the companies with the best financial health in the sector.
Congratulations to the entire Probelte Pharma team, because without you it would not have been possible!!
Plimsoll Certificate of Business Excellence 2023
Evaluation of the efficacy of subcutaneous immunotherapy with polymerised allergenic extract from Dermatophagoides pteronyssinus in patients with hypersensitivity to house dust mites
PROBELTE PHARMA has participated in the project entitled "EVALUATION OF THE EFFICACY OF SUBCUTANEOUSIMMUNOTHERAPY WITH POLYMERISED ALLERGENIC EXTRACT FROM DERMATOPHAGOIDES PTERONYSSINUS INPATIENTS WITH HYPERSENSITIVITY TO HOUSE DUST MITES" funded by the CDTI and the Ministry of Science and Innovation.
Specific immunotherapy with allergen extracts, known as "allergy shots", involves administering an "extract"
of the allergen responsible for the condition, with the aim of inducing the tolerance required to control
the allergic response. To date, it is considered the only treatment capable of altering the
natural course of the disease.
PROBELTE PHARMA has developed a safer allergen immunotherapy treatment based on an allergenic extract from a
house dust mite (Dermatophagoides pteronyssinus) that has been modified through polymerisation with
glutaraldehyde.
The MAIN objective of this research project was to assess the efficacy and safety of a polymerised extract from
D. pteronyssinus that was administered for 12 months to treat rhinoconjunctivitis (with or without asthma) caused by
hypersensitivity to D. pteronyssinus house dust mites in adult patients.
The project (file number IDI20190614C) was funded by the CENTER FOR THE DEVELOPMENTOF INDUSTRIAL TECHNOLOGY-PUBLIC CORPORATE ENTITY (CDTI-EPE) through the "Individual R&D Projects" call for proposals as part
of the Recovery, Transformation and Resilience Plan. The project was launched in March 2019 and ended in June 2023,
with a budget of €1,239,315.00 and a grant of €278,845.88.
Murcia Chamber of Commerce XPANDE Programme
Probelte Pharma, S.L. has been a beneficiary of the European Regional Development Fund (ERDF), whose objective is to improve the competitiveness of SMEs. Thanks to this, we launched an Internationalisation Plan with the aim of improving our global
A way of making Europe!